Drugs / Alanyl-glutamine
Alanyl-glutamine
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT01701193 | Feb 2015 → Oct 2016 | adhesions of uterus | Temple Therapeutics BV | Completed | No outcome recorded |
| Phase 1/2 | NCT01353638 | Apr 2011 → Mar 2012 | end stage renal failure | Christoph Aufricht | Terminated | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04305769 | Jun 2021 → Dec 2026 expected | Clostridium difficile colitis | University of Virginia | Recruiting | No outcome recorded |
| Phase 2 | NCT02053350 | Apr 2015 → Apr 2017 | Clostridium difficile colitis | University of Virginia | Terminated | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT04019184 | Jul 2019 → Feb 2020 | acute kidney injury | University Hospital Muenster | Completed | No outcome recorded |
| Phase 3 | NCT00133562 | Aug 2004 → May 2006 | nutritional disorder | University of Virginia | Withdrawn | No outcome recorded |
| Phase 3 | NCT00338221 | Aug 2004 → Apr 2005 | — | University of Virginia | Withdrawn | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01534663 Comparator | Nov 2011 → Jul 2013 | heart failure | Columbia University | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00922688 Comparator | Dec 2010 → Dec 2012 | colon carcinoma | Medical Center Alkmaar | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Alanyl-glutamine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04305769 ↗ |
| Known as | Alanyl-glutamine-dipeptide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01353638 ↗ |
| Known as | Dipeptiven | “Dipeptiven (Alanyl-glutamine-dipeptide)” NCT01353638 ↗ |
| Known as | L-alanyl-Lglutamine | “Supplementation of l-Alanyl-l-Glutamine and Fish Oil Improves Body Composition and Quality of Life in Patients With Chronic Heart Failure.” PMID 26269566 ↗ Aug 20153“Intravenous infusion of 0.5 g/kg body weight (2.5 ml/kg body weight) L-alanyl-Lglutamine over 12 h after randomization” NCT04019184 ↗ “Sterile solution of L-Alanyl-L-Glutamine, 400mg/mL in water for injection.” NCT01701193 ↗ |
| Modality | Peptide | “given as the dipeptide alanyl-glutamine” NCT00922688 ↗ |
| Route | Intravenous | “Intravenous supplementation of the dipeptide alanyl-glutamine is started 24 hours prior to surgery” NCT00922688 ↗ |